# Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Source: https://onco.cc/trials/nct00557193/  
OnCo record `nct00557193` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Asparaginase, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Etoposide, Filgrastim, Leucovorin, Mercaptopurine, Methotrexate, Prednisone and Vincristine in Acute lymphoblastic leukaemia and Leukaemia, run by Children's Oncology Group, completed.

## Summary

Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia is a phase 3 interventional study registered as NCT00557193 by Children's Oncology Group, with 218 participants recorded, started 2008-01-15 and reaching its primary completion in 2017-09-30. Interventions recorded: Asparaginase, Biospecimen Collection, Bone Marrow Biopsy, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Echocardiography, Etoposide, Filgrastim, Laboratory Biomarker Analysis, Lestaurtinib, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Multigated Acquisition Scan, Pegaspargase, Pharmacological Study, Prednisone, Therapeutic Hydrocortisone, Vincristine Sulfate. Conditions recorded: Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Childhood T Acute Lymphoblastic Leukemia.

Linked to the drug Mercaptopurine because the registry names it among its interventions and Acute lymphoblastic leukaemia and Leukaemia among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00557193
- Phase: 3
- Setting: A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807)
- Sponsor: Children's Oncology Group
- Enrolled: 218

## Sources

- ClinicalTrials.gov NCT00557193: https://clinicaltrials.gov/study/NCT00557193

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/)
- drugs: [Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase)](https://onco.cc/drugs/asparaginase/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Cytarabine](https://onco.cc/drugs/cytarabine/), [Daunorubicin](https://onco.cc/drugs/daunorubicin/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Etoposide](https://onco.cc/drugs/etoposide/), [Filgrastim (G-CSF)](https://onco.cc/drugs/filgrastim/), [Leucovorin (folinic acid)](https://onco.cc/drugs/leucovorin/), [Mercaptopurine](https://onco.cc/drugs/mercaptopurine/), [Methotrexate](https://onco.cc/drugs/methotrexate/), [Prednisone](https://onco.cc/drugs/prednisone/), [Vincristine](https://onco.cc/drugs/vincristine/)

---
JSON: https://onco.cc/api/v1/entities/nct00557193.json